niacinamide has been researched along with Amyotrophic Lateral Sclerosis in 8 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, we aim to verify whether swim training can improve lactate metabolism, NAD+ and NADH levels, as well as modify the activity of glycolytic and NADH shuttle enzymes and monocarboxylate transporters (MCTs) in skeletal muscle of amyotrophic lateral sclerosis (ALS) mice." | 8.12 | Swim Training Affects on Muscle Lactate Metabolism, Nicotinamide Adenine Dinucleotides Concentration, and the Activity of NADH Shuttle Enzymes in a Mouse Model of Amyotrophic Lateral Sclerosis. ( Antosiewicz, J; Cieminski, K; Dzik, KP; Flis, DJ; Kaczor, JJ; Wieckowski, MR; Ziolkowski, W, 2022) |
| "In this study, we aim to verify whether swim training can improve lactate metabolism, NAD+ and NADH levels, as well as modify the activity of glycolytic and NADH shuttle enzymes and monocarboxylate transporters (MCTs) in skeletal muscle of amyotrophic lateral sclerosis (ALS) mice." | 4.12 | Swim Training Affects on Muscle Lactate Metabolism, Nicotinamide Adenine Dinucleotides Concentration, and the Activity of NADH Shuttle Enzymes in a Mouse Model of Amyotrophic Lateral Sclerosis. ( Antosiewicz, J; Cieminski, K; Dzik, KP; Flis, DJ; Kaczor, JJ; Wieckowski, MR; Ziolkowski, W, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cieminski, K | 1 |
| Flis, DJ | 1 |
| Dzik, KP | 1 |
| Kaczor, JJ | 1 |
| Wieckowski, MR | 1 |
| Antosiewicz, J | 1 |
| Ziolkowski, W | 1 |
| Obrador, E | 2 |
| Salvador, R | 2 |
| Marchio, P | 2 |
| López-Blanch, R | 1 |
| Jihad-Jebbar, A | 1 |
| Rivera, P | 1 |
| Vallés, SL | 1 |
| Banacloche, S | 1 |
| Alcácer, J | 1 |
| Colomer, N | 1 |
| Coronado, JA | 1 |
| Alandes, S | 1 |
| Drehmer, E | 2 |
| Benlloch, M | 2 |
| Estrela, JM | 2 |
| Willyard, C | 1 |
| Blacher, E | 2 |
| Bedlack, R | 1 |
| de la Rubia, JE | 1 |
| Platero, JL | 1 |
| Caplliure-Llopis, J | 1 |
| Villaron-Casales, C | 1 |
| de Bernardo, N | 1 |
| AlarcÓn, J | 1 |
| Fuente, C | 1 |
| Carrera, S | 1 |
| Sancho, D | 1 |
| GarcÍa-Pardo, P | 1 |
| Pascual, R | 1 |
| JuÁrez, M | 1 |
| Cuerda-Ballester, M | 1 |
| Forner, A | 1 |
| Sancho-Castillo, S | 1 |
| Barrios, C | 1 |
| Holmes, HE | 1 |
| Dellinger, RW | 1 |
| Guarente, L | 1 |
| Bashiardes, S | 1 |
| Shapiro, H | 1 |
| Rothschild, D | 1 |
| Mor, U | 1 |
| Dori-Bachash, M | 1 |
| Kleimeyer, C | 1 |
| Moresi, C | 1 |
| Harnik, Y | 1 |
| Zur, M | 1 |
| Zabari, M | 1 |
| Brik, RB | 1 |
| Kviatcovsky, D | 1 |
| Zmora, N | 1 |
| Cohen, Y | 1 |
| Bar, N | 1 |
| Levi, I | 1 |
| Amar, N | 1 |
| Mehlman, T | 1 |
| Brandis, A | 1 |
| Biton, I | 1 |
| Kuperman, Y | 1 |
| Tsoory, M | 1 |
| Alfahel, L | 1 |
| Harmelin, A | 1 |
| Schwartz, M | 1 |
| Israelson, A | 1 |
| Arike, L | 1 |
| Johansson, MEV | 1 |
| Hansson, GC | 1 |
| Gotkine, M | 1 |
| Segal, E | 1 |
| Elinav, E | 1 |
| Wang, J | 1 |
| Zhang, Y | 1 |
| Tang, L | 1 |
| Zhang, N | 1 |
| Fan, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial[NCT04244630] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With G04CB02 on the Clinical Improvement of ALS Patients[NCT04654689] | Phase 2 | 90 participants (Actual) | Interventional | 2021-11-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for niacinamide and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
Topics: Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Combinations; El | 2019 |
Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
Topics: Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Combinations; El | 2019 |
Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
Topics: Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Combinations; El | 2019 |
Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
Topics: Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Drug Combinations; El | 2019 |
7 other studies available for niacinamide and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Swim Training Affects on Muscle Lactate Metabolism, Nicotinamide Adenine Dinucleotides Concentration, and the Activity of NADH Shuttle Enzymes in a Mouse Model of Amyotrophic Lateral Sclerosis.
Topics: Adenine; Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Lactic Acid; Malate Dehydro | 2022 |
Nicotinamide Riboside and Pterostilbene Cooperatively Delay Motor Neuron Failure in ALS SOD1
Topics: Acetylcysteine; Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Apoptosis; Cytokines; Female; | 2021 |
How gut microbes could drive brain disorders.
Topics: alpha-Synuclein; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Autism Spectrum Disorder | 2021 |
Can microbes combat neurodegeneration?
Topics: Akkermansia; Amyotrophic Lateral Sclerosis; Animals; Bacteria; Brain; Gastrointestinal Microbiome; H | 2021 |
ALSUntangled 42: Elysium health's "basis".
Topics: Adult; Amyotrophic Lateral Sclerosis; Humans; Male; Niacinamide; Pyridinium Compounds; Stilbenes | 2018 |
Potential roles of gut microbiome and metabolites in modulating ALS in mice.
Topics: Akkermansia; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Disease Models, Animal; | 2019 |
Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Annexin A5; Blotting, Western; Cell Death; Cell Survival; Cells, Cult | 2011 |